1887

Abstract

In this study, we aimed to characterize the epitope recognized by the neutralizing 17H23 mAb directed against the E2 glycoprotein of most of salmonid alphavirus (SAV) subtypes and widely used in several laboratories to routinely diagnose SAV. We hypothesized that the 17H23 epitope was located in the major domain B, previously identified in the E2 of mammalian alphaviruses as the domain recognized by most of the E2 neutralizing mAbs. Indeed, the SAV E2 domain B counterpart is contained in the protein domain previously characterized as being recognized by mAb 17H23. Thus, to precisely characterize the 17H23 epitope, we developed an alanine scanning mutagenesis approach coupled with the generation of the respective recombinant SAV (rSAV) by using the available infectious cDNA. Ten mutant rSAVs termed A–J from E2 aa 223–236 were produced and characterized using indirect immunofluorescence assays on virus-infected cells with mAbs 17H23, 51B8 (another non-neutralizing anti-E2 mAb) and 19F3 directed against the non-structural protein nsp1. Two of the mutant rSAVs (G and H) escaped neutralization by mAb 17H23. In addition, we showed that when juvenile trout were infected by bath immersion with the rSAV mutants, some of them were either totally (D, E and G) or partially (H) attenuated. Together, the data from the and experiments indicated that the putative 17H23 amino acid sequence epitope comprised the short amino acid sequence FTSDS.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000411
2016-04-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/4/893.html?itemId=/content/journal/jgv/10.1099/jgv.0.000411&mimeType=html&fmt=ahah

References

  1. Anonymous 1985 Maladie du sommeil et pollutions expérimentales Technical report no. 118. Laboratoire National de Pathologie des Animaux Aquatiques, CNEVA, Brest, France.
    [Google Scholar]
  2. Biacchesi S., Jouvion G., Mérour E., Boukadiri A., Desdouits M., Ozden S., Huerre M., Ceccaldi P. E., Brémont M. 2015; Rainbow trout (Oncorhynchus mykiss) muscle satellite cells are targets of salmonid alphavirus infection. Vet Res 47:9 [CrossRef]
    [Google Scholar]
  3. Boscher S. K., McLoughlin M., Le Ven A., Cabon J., Baud M., Castric J. 2006; Experimental transmission of sleeping disease in one-year-old rainbow trout, Oncorhynchus mykiss (Walbaum), induced by sleeping disease virus. J Fish Dis 29:263–273 [View Article][PubMed]
    [Google Scholar]
  4. Boucher P. 1995 Etiologie et pathogénie de la Maladie du Pancréas et de la Maladie du Sommeil chez les Salmonidés d'élevage Thesis, University of Rennes 1, Rennes, France.
    [Google Scholar]
  5. Boucher P., Baudin-Laurencin F. 1994; Sleeping disease of salmonids. Bull Eur Assoc Fish Pathol 14:179–180
    [Google Scholar]
  6. Boucher P., Baudin-Laurencin F. B. 1996; Sleeping disease and pancreas disease: comparative histopathology and acquired cross-protection. J Fish Dis 19:303–310 [View Article]
    [Google Scholar]
  7. Bratland A., Nylund A. 2009; Studies on the possibility of vertical transmission of Norwegian salmonid Alphavirus in production of Atlantic salmon in Norway. J Aquat Anim Health 21:173–178 [View Article][PubMed]
    [Google Scholar]
  8. Fox J. M., Long F., Edeling M. A., Lin H., van Duijl-Richter M. K., Fong R. H., Kahle K. M., Smit J. M., Jin J., other authors. 2015; Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163:1095–1107 [View Article][PubMed]
    [Google Scholar]
  9. Fringuelli E., Rowley H. M., Wilson J. C., Hunter R., Rodger H., Graham D. A. 2008; Phylogenetic analyses and molecular epidemiology of European salmonid alphaviruses (SAV) based on partial E2 and nsP3 gene nucleotide sequences. J Fish Dis 31:811–823 [View Article][PubMed]
    [Google Scholar]
  10. Graham D. A., Rowley H. R., Frost P. 2014; Cross-neutralization studies with salmonid alphavirus subtype 1-6 strains: results with sera from experimental studies and natural infections. J Fish Dis 37:683–691 [View Article][PubMed]
    [Google Scholar]
  11. Kongtorp R. T., Stene A., Andreassen P. A., Aspehaug V., Graham D. A., Lyngstad T. M., Olsen A. B., Olsen R. S., Sandberg M., other authors. 2010; Lack of evidence for vertical transmission of SAV 3 using gametes of Atlantic salmon, Salmo salar L. exposed by natural and experimental routes. J Fish Dis 33:879–888 [View Article][PubMed]
    [Google Scholar]
  12. McLoughlin M. F., Graham D. A. 2007; Alphavirus infections in salmonids – a review. J Fish Dis 30:511–531 [View Article][PubMed]
    [Google Scholar]
  13. McLoughlin M. F., Nelson R. T., Rowley H. M., Cox D. I., Grant A. N. 1996; Experimental pancreas disease in Atlantic salmon Salmo salar post-smolts induced by salmon pancreas disease virus (SPDV). Dis Aquat Org 26:117–124 [CrossRef]
    [Google Scholar]
  14. Mérour E., Brémont M. 2015; Vaccination against diseases caused by salmonid alphavirus. In Fish Vaccination pp 334–340Edited by Gudding R., Lillehaug A., Evensen Ø. Oxford, UK: John Wiley & Sons;
    [Google Scholar]
  15. Mérour E., Lamoureux A., Bernard J., Biacchesi S., Brémont M. 2013; A fully attenuated recombinant salmonid alphavirus becomes pathogenic through a single amino acid change in the E2 glycoprotein. J Virol 87:6027–6030 [View Article][PubMed]
    [Google Scholar]
  16. Moriette C., LeBerre M., Boscher S. K., Castric J., Brémont M. 2005; Characterization and mapping of monoclonal antibodies against the sleeping disease virus, an aquatic alphavirus. J Gen Virol 86:3119–3127 [View Article][PubMed]
    [Google Scholar]
  17. Moriette C., Leberre M., Lamoureux A., Lai T. L., Brémont M. 2006; Recovery of a recombinant salmonid alphavirus fully attenuated and protective for rainbow trout. J Virol 80:4088–4098 [View Article][PubMed]
    [Google Scholar]
  18. Pal P., Fox J. M., Hawman D. W., Huang Y. J., Messaoudi I., Kreklywich C., Denton M., Legasse A. W., Smith P. P., other authors. 2014; Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88:8213–8226 [View Article][PubMed]
    [Google Scholar]
  19. Porta J., Jose J., Roehrig J. T., Blair C. D., Kuhn R. J., Rossmann M. G. 2014; Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J Virol 88:9616–9623 [View Article][PubMed]
    [Google Scholar]
  20. Snyder A. J., Sokoloski K. J., Mukhopadhyay S. 2012; Mutating conserved cysteines in the alphavirus E2 glycoprotein causes virus-specific assembly defects. J Virol 86:3100–3111 [View Article][PubMed]
    [Google Scholar]
  21. Voss J. E., Vaney M. C., Duquerroy S., Vonrhein C., Girard-Blanc C., Crublet E., Thompson A., Bricogne G., Rey F. A. 2010; Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468:709–712 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000411
Loading
/content/journal/jgv/10.1099/jgv.0.000411
Loading

Data & Media loading...

Supplements

Supplementary Data

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error